ARTICLE | Clinical News
ZD 0473: Began Phase I testing
November 22, 1999 8:00 AM UTC
AnorMed Inc. (TSE:AOM), Langley, B.C. Product: ZD 0473 Business: Cancer Therapeutic category: Cytotoxic Target: DNA Description: Platinum-based therapeutic Indication: Treat cancer Status: Partner As...